TEVA(Teva Pharmaceutical Industries Limited) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $15.88B | $14.93B | $15.85B | $16.54B | $17.26B |
| 毛利润 | $7.59B | $6.97B | $7.64B | $8.06B | $8.94B |
| 营业利润 | $1.72B | −$2.20B | $433.00M | −$303.00M | $2.16B |
| 净利润 | $417.00M | −$2.45B | −$559.00M | −$1.64B | $1.41B |
| 经营现金流 | $798.00M | $1.59B | $1.37B | $1.25B | $1.65B |
| 自由现金流 | $236.00M | $1.04B | $842.00M | $749.00M | $1.15B |
| 摊薄每股收益 | $0.38 | $-2.20 | $-0.50 | $-1.45 | $1.21 |